Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W7DK
|
|||
Former ID |
DNC001939
|
|||
Drug Name |
ISIS 110064
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Nucleolin messenger RNA (NCL mRNA) | Target Info | . | [1] |
KEGG Pathway | Pathogenic Escherichia coli infection | |||
NetPath Pathway | TCR Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Pathway Interaction Database | Aurora B signaling | |||
Validated targets of C-MYC transcriptional activation | ||||
Regulation of Telomerase | ||||
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
WikiPathways | Pathogenic Escherichia coli infection | |||
miR-targeted genes in squamous cell - TarBase | ||||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
miR-targeted genes in epithelium - TarBase |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 6,165,786, Antisense modulation of nucleolin expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.